Zimmer Biomet Holdings (NYSE:ZBH) witnessed a selling pressure and the shares last traded with a loss of -0.99 points or -0.83% at $118.24. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $52.01 million with an inflow of $80.85 million in upticks and an outflow of $28.84 million in downticks. Using the data, the up/down ratio is found to be 2.8. The share price has recorded -2.94% on a weekly basis.A block trade of $54.79 million in uptick and $2.5 million in downtick was also observed, resulting in an up/down ratio of 21.93. The net money flow of the block trade stood at a $52.29, signaling heavy buying.
Currently the company Insiders own 1.22% of Zimmer Biomet Holdings shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -43.64% . Institutional Investors own 90.52% of Zimmer Biomet Holdings shares. During last six month period, the net percent change held by insiders has seen a change of -43.64%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Williamson Daniel E., officer (Group President) of Zimmer Biomet Holdings, Inc., had unloaded 10,000 shares at an average price of $119.77 in a transaction dated on June 9, 2016. The total value of the transaction was worth $1,197,700.
Zimmer Biomet Holdings (NYSE:ZBH) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.99 points or 0.83% at $118.24 with 1,578,051 shares getting traded. Post opening the session at $118.47, the shares hit an intraday low of $118.17 and an intraday high of $119.96 and the price was in this range throughout the day. The company has a market cap of $23,558 million and the number of outstanding shares have been calculated to be 199,238,890 shares. The 52-week high of Zimmer Biomet Holdings (NYSE:ZBH) is $123.43 and the 52-week low is $88.27.
Many analysts have stated their opinion on the company shares. Guggenheim Securities initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH). The rating major has initiated the coverage with neutral rating on the shares. The rating by the firm was issued on June 9, 2016.
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc. is a musculoskeletal healthcare company. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company manages its operations through three geographic segments: the Americas, comprising principally of the United States and includes other North, Central and South American markets; Europe, comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers, and directly to dental practices and dental laboratories.